INNOVACAP
Innova Captab Limited (INNOVACAP) Stock Analysis
Innova Captab Limited manufactures pharmaceutical formulations across therapeutic segments for India and exports. It has API and finished-dosage capabilities with a growing product portfolio. The company targets generics and contract opportunities. It is a listed pharma company.
Healthcare › Drug Manufacturers - Specialty & Generic
₹1,281.00
+8.58% 1W | +54.50% 52W
Market Cap
7.3k CR
P/E Ratio
47.7
52W High
₹1353.5
52W Low
₹622
Div. Yield
0.31%
Beta
-0
50 DMA
₹1057.1
200 DMA
₹844.2
Profit Margin
8.8%
Inst. Own.
18.9%
🚀 BREAKOUT
🚀 BREAKOUT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 233 | 283 | 302 | 263 | 294 | 318 | 316 | 315 | 352 | 380 | 450 | 448 | 471 |
| Expenses | 202 | 242 | 258 | 225 | 252 | 268 | 270 | 267 | 299 | 329 | 381 | 383 | 398 |
| Operating Profit | 31 | 40 | 45 | 38 | 42 | 50 | 47 | 48 | 52 | 52 | 69 | 65 | 73 |
| OPM % | 13% | 14% | 15% | 14% | 14% | 16% | 15% | 15% | 15% | 14% | 15% | 15% | 16% |
| Other Income | 1 | 3 | 2 | 6 | 2 | 2 | 4 | 3 | 4 | 4 | 2 | 2 | 2 |
| Interest | 5 | 9 | 7 | 1 | 0 | 0 | 0 | 2 | 3 | 6 | 4 | 5 | 4 |
| Depreciation | 3 | 5 | 5 | 3 | 5 | 5 | 5 | 10 | 11 | 11 | 11 | 11 | 12 |
| Profit before tax | 25 | 30 | 35 | 40 | 39 | 47 | 46 | 39 | 43 | 39 | 56 | 51 | 59 |
| Tax % | 28% | 24% | 29% | 27% | 25% | 25% | 25% | 25% | 27% | 24% | 24% | 25% | 25% |
| Net Profit | 18 | 23 | 25 | 29 | 29 | 35 | 34 | 30 | 31 | 30 | 42 | 38 | 44 |
| EPS in Rs | 3.66 | 4.77 | 4.39 | 5.02 | 5.15 | 6.12 | 5.98 | 5.17 | 5.42 | 5.18 | 7.37 | 6.65 | 7.71 |
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 356 | 373 | 411 | 801 | 926 | 1,081 | 1,244 | 1,630 | 1,749 |
| Expenses | 315 | 322 | 356 | 704 | 813 | 927 | 1,057 | 1,387 | 1,490 |
| Operating Profit | 41 | 51 | 54 | 96 | 114 | 154 | 186 | 243 | 259 |
| OPM % | 11% | 14% | 13% | 12% | 12% | 14% | 15% | 15% | 15% |
| Other Income | 0 | 1 | 1 | 3 | 9 | 12 | 12 | 7 | 9 |
| Interest | 6 | 5 | 4 | 6 | 20 | 21 | 2 | 17 | 18 |
| Depreciation | 11 | 10 | 6 | 8 | 11 | 16 | 25 | 45 | 46 |
| Profit before tax | 25 | 38 | 46 | 86 | 92 | 130 | 171 | 188 | 205 |
| Tax % | 20% | 26% | 26% | 25% | 26% | 27% | 25% | 25% | |
| Net Profit | 20 | 28 | 34 | 64 | 68 | 94 | 128 | 141 | 154 |
| EPS in Rs | 165.67 | 232.42 | 287.50 | 532.92 | 14.16 | 16.49 | 22.41 | 24.63 | 26.91 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 8% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 21.0% | 32.0% | – |
| Profit CAGR | 28.0% | 32.0% | – |
Shareholding Pattern
Promoters50.90%
FIIs0.23%
DIIs19.67%
Public29.20%
Promoters50.90%
FIIs0.08%
DIIs20.17%
Public28.86%
Promoters50.90%
FIIs0.10%
DIIs20.24%
Public28.76%
Promoters50.90%
FIIs0.23%
DIIs20.14%
Public28.74%
Promoters50.90%
FIIs0.34%
DIIs19.92%
Public28.84%
Promoters50.90%
FIIs1.94%
DIIs20.78%
Public26.39%
Promoters50.90%
FIIs0.35%
DIIs19.77%
Public29.00%
Promoters50.90%
FIIs0.23%
DIIs20.14%
Public28.74%
Promoters50.90%
FIIs0.34%
DIIs19.92%
Public28.84%
INNOVACAP
Holdings Analysis
Key strengths & risk signals
79
Overall
74
Fundamental
85
Technical
Risks (2)
LOW MARGIN! 8.8% profit margin - thin profits.
OVERBOUGHT! RSI at 75.6 - caution, may pull back.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (1057.1) is above 200-day average (844.2) - positive signal.
BREAKOUT! Stock has broken above resistance levels with momentum.
EXCELLENT YEAR! Stock gained 54.5% in the last year.
Fundamental & Technical Analysis
79Overall
74Fundamental
85Technical
Fundamental Breakdown
Growth Quality
30/30
Revenue CAGR: 20.1% (EXCELLENT, 15/15). Profit CAGR: 27.5% (EXCELLENT, 15/15).
Profit Margin
3/10
LOW MARGIN! 8.8% profit margin - thin profits.
PEG Valuation
8/10
FAIRLY VALUED! PEG of 1.73 indicates reasonable valuation.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.31% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
10/20
SIGNIFICANT PUBLIC HOLDING! 35.22% public ownership - moderate retail influence.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (1057.1) is above 200-day average (844.2) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (1281.0) is above both moving averages.
Trend Pattern
20/20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 54.5% in the last year.
Volume Sentiment
20/30
BULLISH SENTIMENT! In last 30 days: 17 up days, 13 down days. Avg volume on up days: 129,340 vs down days: 114,310. Ratio: 1.13x
RSI
2/5
OVERBOUGHT! RSI at 75.6 - caution, may pull back.
52W Range
5/5
STRONG! Trading at 90.1% of 52W range - near yearly highs.
Momentum
5/5
STRONG MOMENTUM! Price has grown across all timeframes - up 8.6% (1 week), 24.2% (1 month), 36.1% (3 months). Momentum is accelerating.
Beta
3/5
MARKET ALIGNED! Beta of 1.00 - moves with the market.
INNOVACAP
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-14 | Concall PDF | |
| Q4FY262026-05-14 | Concall PDF | |
| Q3FY262026-02-02 | Concall PDF | |
| Q2FY262025-11-13 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INNOVACAP | ₹1,281.00 | 47.7 | 8.8% | 20.1% | 27.5% | +54.5% | 79 | BREAKOUT | +42.3% | +15.7% | +34.0% | +5.2% |
| BLISSGVS | ₹704.70 | 55.8 | 13.5% | 7.2% | 22.1% | +373.6% | 76 | BOUNCE FROM SUPPORT | +16.5% | +40.7% | +37.6% | +11.1% |
| SPARC | ₹209.10 | 4.3 | 83.0% | -45.3% | – | +54.8% | 69 | BREAKOUT | -59.9% | -101.2% | +315.6% | -97.8% |
| MOREPENLAB | ₹120.40 | 46.8 | 7.2% | 8.4% | 34.9% | +138.6% | 73 | BREAKDOWN | +427.1% | +259.2% | +34.1% | +17.6% |
| AARTIPHARM | ₹939.50 | 41.9 | 10.4% | -2.6% | -3.3% | +11.5% | 60 | APPROACHING RESISTANCE | +65.4% | +24.5% | +38.7% | -8.0% |
| IOLCP | ₹204.20 | 35.8 | 6.7% | 1.6% | -0.4% | +95.6% | 61 | CONSOLIDATING UP | +90.0% | +21.1% | +37.1% | +22.1% |
| SEQUENT | ₹201.20 | 123.4 | 2.5% | 3.1% | -18.9% | +26.2% | 55 | CONSOLIDATION | -13.9% | +161.2% | +10.9% | +102.5% |
| PGHL | ₹5,406.00 | 25.2 | 24.9% | 8.2% | 19.3% | -13.3% | 73 | BOUNCE FROM SUPPORT | +45.3% | +1.7% | +7.4% | -1.8% |
Data from TradeAlone · Updated daily
